500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

Kodu・Aktsiate loetelu・DBV Technologies SA

D
DBV Technologies SA

Suletud

3.805 1.87

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.625

Max

3.895

Põhinäitajad
By Trading Economics
Sissetulek	8.7M -33M
Aktsiakasum	-0.1
Kasumimarginaal	-1,888.814
Töötajad	117
EBITDA	7.5M -31M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+47.85% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. apr 2026

Turustatistika
By TradingEconomics
Turukapital	-15M 421M
Eelmine avamishind	1.94
Eelmine sulgemishind	3.805

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

1.61 / 1.72 Toetus ja vastupanu

DBV Technologies SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. märts 2026, 19:32 UTC

Omandamised, ülevõtmised, äriostud

Diana Shipping Increases Offer to Acquire Genco -- Update

6. märts 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6. märts 2026, 22:26 UTC

Uudisväärsed sündmused

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6. märts 2026, 22:07 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

6. märts 2026, 21:37 UTC

Tulu

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6. märts 2026, 21:25 UTC

Uudisväärsed sündmused

How The Iran War Impacts Ukraine. -- Barrons.com

6. märts 2026, 21:17 UTC

Tulu

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6. märts 2026, 20:50 UTC

Tulu

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6. märts 2026, 20:46 UTC

Tulu

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6. märts 2026, 20:31 UTC

Uudisväärsed sündmused

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6. märts 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6. märts 2026, 20:12 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6. märts 2026, 19:10 UTC

Market Talk

Uudisväärsed sündmused

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6. märts 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6. märts 2026, 18:44 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6. märts 2026, 18:08 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6. märts 2026, 17:46 UTC

Uudisväärsed sündmused

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6. märts 2026, 17:40 UTC

Market Talk

Tulu

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6. märts 2026, 17:40 UTC

Tulu

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6. märts 2026, 17:32 UTC

Market Talk

Uudisväärsed sündmused

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6. märts 2026, 17:28 UTC

Market Talk

Uudisväärsed sündmused

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6. märts 2026, 17:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

6. märts 2026, 17:20 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

6. märts 2026, 17:20 UTC

Omandamised, ülevõtmised, äriostud

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Võrdlus sarnastega

Hinnamuutus

DBV Technologies SA Prognoos

Hinnasiht

By TipRanks

47.85% tõus

12 kuu keskmine prognoos

Keskmine 5.5 EUR 47.85%

Kõrge 5.5 EUR

Madal 5.5 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi DBV Technologies SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi DBV Technologies SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.61 / 1.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.